TTR and amyloidosis: Most therapeutic approaches have focused on reducing the concentration of the amyloid-forming precursor protein by using anti-plasma cell chemotherapy, anti-inflammatory drugs, antisense oligonucleotides, or with protein-stabilizing small molecules for AL-, AA-, and ATTR-associated amyloidoses, respectively (33–35).